Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPCY: Youth HIV Prevention and Care in Uganda
NCT06474364Phase 4Recruiting
- Sponsor
- MU-JHU Research Collaboration
- Start
- Aug 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cabotegravir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by MU-JHU Research Collaboration. Primary endpoints: Implementation science outcomes (Feasibility, Acceptability, Adoption, Maintenance) at 18 months, Effectiveness of 2 delivery models of increasing uptake and persistence of CABLA at 24 months and 3 more. Started Aug 2024; status: recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06474364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474364.